HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 76.2%

Neg 0% Neu 0% Pos 76.2%

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.